| Autor: |
Osman FH; School of Medicine, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK., Chan VW; Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9JT, UK.; Royal Derby Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Derby DE22 3NE, UK.; Division of Surgery and Interventional Science, University College London, London WC1E 6BT, UK., Breen DJ; Department of Radiology, Southampton University Hospitals, Southampton SO16 6YD, UK., King A; Department of Radiology, Southampton University Hospitals, Southampton SO16 6YD, UK., Nielsen TK; Department of Urology, Aarhus University Hospital, 8200 Aarhus, Denmark., Garnon J; Department of Interventional Radiology, Nouvel Hôpital Civil, 1 Place de l'Hôpital, 67000 Strasbourg, France., Alcorn D; Department of Interventional Radiology, Gartnavel General Hospital, Glasgow G12 0YN, UK., Lagerveld B; Department of Urology, OLVG, Amsterdam 1091 AC, The Netherlands., Graumann O; Department of Radiology, Odense University Hospital, 5000 Odense, Denmark., Keeley FX Jr; Bristol Urological Institute, North Bristol NHS Trust, Bristol BS10 5NB, UK., Walkden M; Department of Imaging, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK., de Kerviler É; Radiology Department, Saint-Louis Hospital, AP-HP, 1 Avenue Claude-Vellefaux, 75475 Paris, CEDEX 10, France., Wah TM; Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9JT, UK.; Department of Diagnostic and Interventional Radiology, Institute of Oncology, St. James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK. |
| Abstrakt: |
This study aims to evaluate the safety, efficacy, and renal function preservation of percutaneous cryoablation (PCA) for small renal masses (SRMs) in inherited RCC syndromes. Patients with inherited T1N0M0 RCCs (<7 cm) undergoing PCA from 2015 to 2021 were identified from the European Registry for Renal Cryoablation (EuRECA). The primary outcome was local recurrence-free survival (LRFS). The secondary outcomes included technical success, peri-operative outcomes, and other oncological outcomes estimated using the Kaplan-Meier method. Simple proportions, chi-squared tests, and t -tests were used to analyse the peri-operative outcomes. A total of 68 sessions of PCA were performed in 53 patients with RCC and 85 tumours were followed-up for a mean duration of 30.4 months (SD ± 22.0). The overall technical success rate was 99%. The major post-operative complication rate was 1.7%. In total, 7.4% (2/27) of patients had >25% reduction in renal function. All oncological events were observed in VHL patients. Estimated 5-year LRFS, metastasis-free survival, cancer-specific survival, and overall survival were 96.0% (95% CI 75-99%), 96.4% (95% CI 77-99%), 90.9% (95% CI 51-99%), and 90.9% (95% CI 51-99%), respectively. PCA of RCCs for patients with hereditary RCC SRMs appears to be safe, offers low complication rates, preserves renal function, and achieves good oncological outcomes. |
